Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.
Falantes JF, Márquez-Malaver FJ, Carrillo E, Culebras MG, Morales R, Prats C, Vargas MT, Caballero T, Rodríguez-Arbolí E, Espigado I, Pérez-Simón JA. Falantes JF, et al. Among authors: marquez malaver fj. Clin Lymphoma Myeloma Leuk. 2022 Dec;22(12):e1059-e1066. doi: 10.1016/j.clml.2022.08.012. Epub 2022 Aug 27. Clin Lymphoma Myeloma Leuk. 2022. PMID: 36117041
Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF, Calderón C, Márquez Malaver FJ, Alonso D, Martín Noya A, Carrillo E, Martino ML, Montero I, González J, Parody R, Espigado I, Pérez-Simón JA. Falantes JF, et al. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):144-52. doi: 10.1016/j.clml.2012.09.013. Epub 2012 Nov 6. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23137720
Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
Falantes JF, Calderón C, Márquez-Malaver FJ, Aguilar-Guisado M, Martín-Peña A, Martino ML, Montero I, González J, Parody R, Pérez-Simón JA, Espigado I. Falantes JF, et al. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):80-6. doi: 10.1016/j.clml.2013.09.014. Epub 2013 Oct 1. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24220615
Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.
Falantes JF, Trujillo P, Piruat JI, Calderón C, Márquez-Malaver FJ, Martín-Antonio B, Millán A, Gómez M, González J, Martino ML, Montero I, Parody R, Espigado I, Urbano-Ispizua A, Pérez-Simón JA. Falantes JF, et al. Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):236-44. doi: 10.1016/j.clml.2014.10.003. Epub 2014 Oct 23. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25487600
Evaluation of Parameters Related to the Probability of Leukemic Progression in Patients With Lower-Risk Myelodysplastic Syndrome.
Falantes JF, Márquez-Malaver FJ, Calderón-Cabrera C, Pedrote B, Martino ML, González J, Espigado I, Pérez-Simón JA. Falantes JF, et al. Among authors: marquez malaver fj. Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):469-474.e1. doi: 10.1016/j.clml.2018.05.004. Epub 2018 May 10. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29807802
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.
Falantes J, Delgado RG, Calderón-Cabrera C, Márquez-Malaver FJ, Valcarcel D, de Miguel D, Bailén A, Bargay J, Bernal T, González-Porras JR, Tormo M, Ramos F, Andreu R, Xicoy B, Nomdedeu B, Brunet S, Sánchez J, Jurado AF, Bonanad S, Pérez-Simón JA, Sanz G; Spanish Group of Myelodysplastic Syndromes (GESMD). Falantes J, et al. Leuk Res. 2015 Jan;39(1):52-7. doi: 10.1016/j.leukres.2014.10.004. Epub 2014 Oct 30. Leuk Res. 2015. PMID: 25487012 Clinical Trial.
Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia: A Retrospective Analysis from the Time of Transplant Approval.
Rodríguez-Arbolí E, Márquez-Malaver FJ, Rodríguez-Torres N, Caballero-Velázquez T, Escamilla-Gómez V, Calderón-Cabrera C, Falantes-González JF, Solé-Rodríguez M, García-Ramírez P, Moya-Arnao M, Carreras E, Espigado-Tocino I, Pérez-Simón JA. Rodríguez-Arbolí E, et al. Among authors: marquez malaver fj. Biol Blood Marrow Transplant. 2019 Jan;25(1):183-190. doi: 10.1016/j.bbmt.2018.08.019. Epub 2018 Aug 25. Biol Blood Marrow Transplant. 2019. PMID: 30153492 Free article.
29 results